{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.43","upperLimit":"7.78","value":"5.6"},{"groupId":"OG001","lowerLimit":"3.55","upperLimit":"7.95","value":"5.75"}]}],"title":"Change from baseline at cycle 1 (n =521, 495)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.23","upperLimit":"7.55","value":"5.39"},{"groupId":"OG001","lowerLimit":"4.05","upperLimit":"8.42","value":"6.23"}]}],"title":"Change from baseline at cycle 2 (n = 502, 492)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.21","upperLimit":"6.57","value":"4.39"},{"groupId":"OG001","lowerLimit":"3.89","upperLimit":"8.3","value":"6.09"}]}],"title":"Change from baseline at cycle 3 (n = 459, 452)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.73","upperLimit":"5.14","value":"2.94"},{"groupId":"OG001","lowerLimit":"1.98","upperLimit":"6.42","value":"4.2"}]}],"title":"Change from baseline at cycle 4 (n = 421, 415)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.46","upperLimit":"4.04","value":"1.79"},{"groupId":"OG001","lowerLimit":"1.08","upperLimit":"5.59","value":"3.33"}]}],"title":"Change from baseline at cycle 5 (n = 339, 365)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.26","upperLimit":"4.88","value":"2.57"},{"groupId":"OG001","lowerLimit":"0.06","upperLimit":"4.64","value":"2.35"}]}],"title":"Change from baseline at cycle 6 (n = 275, 320)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.25","upperLimit":"4.99","value":"2.62"},{"groupId":"OG001","lowerLimit":"0.38","upperLimit":"5.06","value":"2.72"}]}],"title":"Change from baseline at cycle 7 (n = 229, 267)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-1.08","upperLimit":"3.78","value":"1.35"},{"groupId":"OG001","lowerLimit":"-0.42","upperLimit":"4.37","value":"1.98"}]}],"title":"Change from baseline at cycle 8 (n = 196, 226)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-1.4","upperLimit":"3.6","value":"1.1"},{"groupId":"OG001","lowerLimit":"-1.5","upperLimit":"3.51","value":"1"}]}],"title":"Change from baseline at cycle 9 (n = 164, 172)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-2.57","upperLimit":"2.61","value":"0.02"},{"groupId":"OG001","lowerLimit":"-1.26","upperLimit":"3.93","value":"1.33"}]}],"title":"Change from baseline at cycle 10 (n = 137, 141)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-5.69","upperLimit":"-0.51","value":"-3.1"},{"groupId":"OG001","lowerLimit":"-4.65","upperLimit":"0.46","value":"-2.09"}]}],"title":"Change from baseline at Follow-up 1 (n = 137, 153)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"521"},{"groupId":"OG001","value":"495"}],"units":"Participants"}],"description":"FACT-P is a 39-item participant questionnaire that measures the concerns of participants with prostate cancer. It consists of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). FACT-P Total Score sums all 5 sub-scales to give a score in the range of 0 to 156, where higher values represent better HRQoL.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cabazitaxel 20 mg/m\\^2 IV infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.","id":"OG000","title":"Cabazitaxel 20 mg/m^2"},{"description":"Cabazitaxel 25 mg/m\\^2 IV infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.","id":"OG001","title":"Cabazitaxel 25 mg/m^2"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Analysis was performed on FACT-P population. Number of participants analyzed=participants with evaluable FACT-P Total Score for specified outcome measure. Here, 'n' signifies number of participants with available data for specified category.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 1 of each Cycle 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 (each cycle 21-day); post-treatment follow up 1 (up to 12 weeks)","title":"Change From Baseline in FACT-P:Total Score as a Measure of HRQoL","type":"SECONDARY","unitOfMeasure":"units on a scale"}